ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Endometrial Cancer
Ovarian Epithelial Carcinoma
Breast Cancer
Cancer
Fallopian Tube Cancer
Non-Small-Cell Lung Carcinoma
Colorectal Cancer

Ovarian Cancer trials near Charlotte, NC, USA:

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer (MAIA-ovarian)

The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in partici ...

Enrolling
Ovarian Cancer
Ovarian Cancer Recurrent
Drug: Normal Saline
Drug: COM701

Phase 1, Phase 2

Compugen

Charlotte, North Carolina, United States and 27 other locations

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and prima...

Enrolling
Primary Peritoneal Cancer
Platinum-refractory Ovarian Cancer
Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin

Phase 3

Genelux

Charlotte, North Carolina, United States and 32 other locations

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Charlotte, North Carolina, United States and 176 other locations

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling
Low Grade Serous Ovarian Cancer
Drug: Defactinib
Drug: Letrozole

Phase 3

Verastem

Charlotte, North Carolina, United States of America and 106 other locations

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the s...

Enrolling
Primary Peritoneal Cancer
Epithelial Ovarian Cancer
Drug: Mirvetuximab Soravtansine
Drug: Bevacizumab

Phase 2

AbbVie
AbbVie

Charlotte, North Carolina, United States and 69 other locations

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)

Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular ...

Active, not recruiting
Ovarian Neoplasms
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Drug: Dostarlimab-Placebo
Drug: Standard of care

Phase 3

Tesaro
Tesaro

Charlotte, North Carolina, United States and 181 other locations

Locations recently updated

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian...

Enrolling
Ovarian Cancer
Drug: INCB123667
Drug: Investigator's choice of chemotherapy

Phase 3

Incyte
Incyte

Charlotte, North Carolina, United States and 192 other locations

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian...

Enrolling
Endometrial Cancer
Platinum Resistant Ovarian Cancer
Drug: HWK-016, MUCIN-16-targeted ADC
Drug: Bevacizumab

Phase 1

Whitehawk Therapeutics, Inc.

Charlotte, North Carolina, United States and 11 other locations

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab,...

Active, not recruiting
Carcinoma, Ovarian Epithelial
Ovarian Cancer
Drug: Paclitaxel
Drug: Bevacizumab

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Charlotte, North Carolina, United States and 187 other locations

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerab...

Enrolling
Breast Cancer
Ovarian Cancer
Drug: SON-DP

Phase 1

Qurgen

Huntersville, North Carolina, United States of America and 4 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems